Pomerantz Law Firm Alerts Investors on Class Action for Zenas BioPharma, Inc.
Pomerantz Law Firm Alerts Investors on Class Action for Zenas BioPharma, Inc.
In a significant legal development, Pomerantz LLP has officially announced the initiation of a class action lawsuit against Zenas BioPharma, Inc. (NASDAQ: ZBIO). This lawsuit is aimed at protecting investors who have experienced losses due to the company's business practices. The firm urges any affected investor to reach out for more information and to participate in the legal proceedings.
Background of the Lawsuit
The crux of the complaint revolves around allegations of securities fraud and other unlawful practices by Zenas and certain officers and directors of the company. Investors are particularly concerned about the discrepancies in the company's statements regarding its financial health following its initial public offering (IPO) on September 13, 2024.
Zenas raised approximately $224 million in its IPO by selling 13.235 million shares at a price of $17.00 each. However, following the IPO, the company's stock faced a significant decline, leading to concerns amongst shareholders. The situation escalated after Zenas revealed in its third-quarter report on November 12, 2024, that the company could only support its operations for
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.